WO1998021343B1 - Genes encoding telomerase proteins - Google Patents
Genes encoding telomerase proteinsInfo
- Publication number
- WO1998021343B1 WO1998021343B1 PCT/US1997/021248 US9721248W WO9821343B1 WO 1998021343 B1 WO1998021343 B1 WO 1998021343B1 US 9721248 W US9721248 W US 9721248W WO 9821343 B1 WO9821343 B1 WO 9821343B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- polypeptide
- nucleic acid
- acid molecule
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
Disclosed are nucleic acid molecules encoding polypeptides of the telomerase complex. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
Claims
1. A TP2 nucleic acid molecule encoding a polypeptide selected from the group consisting of: (a) the nucleic acid molecule of SEQ ID
NO: 13;
(b) the nucleic acid molecule that is nucleotides 1920-2820 of SEQ ID NO:13;
(c) the nucleic acid molecule of SEQ ID NO: 19 (d) a nucleic acid molecule encoding the polypeptide of SEQ ID NO: 14, or a biologically active fragment thereof;
(e) a nucleic acid molecule encoding the polypeptide of SEQ ID NO:20, or a biologically active fragment thereof;
(f) a nucleic acid molecule that encodes a polypeptide that is at least 90 percent identical to the polypeptide of SEQ ID NO: 14;
(g) a nucleic acid molecule that encodes a polypeptide that is at least 90 percent identical to the polypeptide of SEQ ID NO: 20;
(h) a nucleic acid molecule that hybridizes under stringent conditions to any of (a) - (g) above; and (i) a nucleic acid molecule that is the complement of any of (a) - (g) above.
2. The nucleic acid molecule that is SEQ ID NO: 13 or SEQ ID NO: 19.
3. The nucleic acid molecule that is nucleotides 1920-2820 of SEQ ID NO:13.
4. A nucleic acid molecule encoding the polypeptide of SEQ ID NO: 14 of SEQ ID NO:20. - 104 -
5. A nucleic acid molecule selected from the group consisting of: nucleotides 1-1689 of SEQ ID N0:13, nucleotides 1-1920 of SEQ ID NO:13, nucleotides 1920-2820 of SEQ ID NO:13, nucleotides 2089-2820 of SEQ ID NO: 13, and nucleotides 2089-2859 of SEQ ID NO: 13.
6. A nucleic acid molecule encoding amino acids 640-940 of the polypeptide of SEQ ID NO:14.
7. A vector comprising the nucleic acid molecule of claim 1.
8. A vector comprising the nucleic acid molecule of claim 2.
9. A vector comprising the nucleic acid molecule of claim 3.
10. A vector comprising the nucleic acid molecule of claim 4.
11. A vector comprising the nucleic acid molecule of claim 5.
12. A vector comprising the nucleic acid molecule of claim 6.
13. A host cell comprising the vector of claim 7.
14. A host cell comprising the vector of claim 8.
15. A host cell comprising the vector of claim 9. - 105 -
16. A host cell comprising the vector of claim 10
17. A host cell comprising the vector of claim 11.
A host cell comprising the vector of claim 12.
19. A process for producing a TP2 polypeptide comprising the steps of:
(a) expressing a polypeptide encoded by the nucleic acid of claim 1 in a suitable host; and (b) isolating the polypeptide.
20. The process of claim 19 wherein the polypeptide is SEQ ID NO: 14 or SEQ ID NO: 20.
21. The process of claim 19 wherein the polypeptide is amino acids 640-940 of SEQ ID NO: 14.
22. A TP2 polypeptide selected from the group consisting of : (a) the polypeptide of SEQ ID NO: 14;
(b) the polypeptide that is amino acids 640- 940 of SEQ ID NO: 14;
(c) the polypeptide of SEQ ID NO:20; and
(d) a polypeptide that is at least 90 percent identical to any of the polypeptides of (a) - (c) .
23. A TP2 polypeptide that is the polypeptide of SEQ ID NO: 14, SEQ ID NO: 20, or a biologically active fragment thereof. - 106 -
24. A TP2 polypeptide selected from the group consisting of: amino acids 1-563 of SEQ ID NO: 14; amino acids 1-640 of SEQ ID NO: 14; amino acids 640-940 of SEQ ID NO: 14; amino acids 696-940 of SEQ ID NO: 14; and amino acids 696-953 of SEQ ID NO: 14.
25. The TP2 polypeptide of claim 22 that does not possess an amino terminal methionine.
26. A method of increasing proliferation of a cell, comprising expressing a nucleic acid encoding TP2 or a biologically active fragment thereof, in the cell.
27. A method of increasing telomerase activity in a cell, comprising expressing a TP2 gene, or a biologically active fragment thereof, in the cell.
28. A method of decreasing telomerase in a cell, comprising expressing a TP2 mutant in a cell, wherein the mutant does not have TP2 biological activity.
29. A nucleic acid molecule encoding a mutant TP2 polypeptide, wherein the codon for aspartic acid at amino acid position 868 or 869 is changed to a codon for alanine.
30. A nucleic acid molecule encoding a mutant TP2 polypeptide, wherein the codons for aspartic acid at amino acid positions 868 and 869 are changed to codons for alanine.
31. A polypeptide encoded by the nucleic acid molecule of claim 29. - 107 -
32. A polypeptide encoded by the nucleic acid molecule of claim 30.
33. A TRIP1 nucleic acid molecule encoding a polypeptide selected from the group consisting of:
(a) the nucleic acid molecule of SEQ ID N0:1;
(b) the nucleic acid molecule of SEQ ID NO: 2;
(c) a nucleic acid molecule encoding the polypeptide of SEQ ID NO: 3, SEQ ID NO: 4, or a biologically active fragment thereof;
(d) a nucleic acid molecule that encodes a polypeptide that is at least 70 percent identical to the polypeptide of SEQ ID NO: 3 or SEQ ID NO : 4 ; (e) a nucleic acid molecule that hybridizes under stringent conditions to any of (a) - (d) above; and
(f) a nucleic acid molecule that is the complement of any of (a) - (e) above.
34. The nucleic acid molecule that is SEQ ID
NO:l.
35. The nucleic acid molecule that is SEQ ID
NO: 2.
36. A nucleic acid molecule encoding the polypeptide of SEQ ID NO : 3.
37. A nucleic acid molecule encoding the polypeptide of SEQ ID NO: 4.
38. A nucleic acid molecule encoding amino acids 1-871 of the polypeptide of SEQ ID NO: 3. - 108 -
39. A vector comprising the nucleic acid molecule of claim 33.
40. A vector comprising the nucleic acid molecule of claim 34.
41. A vector comprising the nucleic acid molecule of claim 35.
42. A vector comprising the nucleic acid molecule of claim 36.
43. A vector comprising the nucleic acid molecule of claim 37.
44. A vector comprising the nucleic acid molecule of claim 38.
45. A host cell comprising the vector of claim 39.
46. A host cell comprising the vector of claim 40.
47. A host cell comprising the vector of claim 41.
48. A host cell comprising the vector of claim 42.
49. A host cell comprising the vector of claim 43.
50. A host cell comprising the vector of claim 44. - 109 -
51. A process for producing a TRIP1 polypeptide comprising the steps of:
(a) expressing a polypeptide encoded by the nucleic acid of claim 1 in a suitable host; and
(b) isolating the polypeptide.
52. The process of claim 51 wherein the polypeptide is SEQ ID NO: 3.
53. The process of claim 51 wherein the polypeptide amino acids 1-871 of SEQ ID NO: 3.
54. A TRIP1 polypeptide selected from the group consisting of:
(a) the polypeptide of SEQ ID NO: 3;
(b) the polypeptide that is amino acids 1-871 of SEQ ID NO: 3; and
(c) a polypeptide that is at least 70 percent identical to the polypeptide of (a) or (b) .
55. A TRIP1 polypeptide that is the polypeptide of SEQ ID NO: 3 or a biologically active fragment thereof .
56. The TRIP1 polypeptide of claim 52 that does not possess an amino terminal methionine.
- 110 -
STATEMENT UNDER ARTICLE 19
The claims of International Application WO 98/21248, published 22 May 1998, have been amended. Original claims 1 through 32 have not been amended, however, new claims 33 through 56 have been added. Claims 33 through 56 are directed to an aspect of the invention not originally claimed by Applicants. Specifically, claims 33 through 56 encompass telomerase protein 1 and DNA encoding therefor. Such claims are fully supported by the written description and the drawings.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002271718A CA2271718A1 (en) | 1996-11-15 | 1997-11-13 | Genes encoding telomerase proteins |
| JP52294198A JP2001527385A (en) | 1996-11-15 | 1997-11-13 | Gene encoding telomerase protein |
| AU52644/98A AU5264498A (en) | 1996-11-15 | 1997-11-13 | Genes encoding telomerase proteins |
| EP97947600A EP0939823A1 (en) | 1996-11-15 | 1997-11-13 | Genes encoding telomerase proteins |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/751,189 | 1996-11-15 | ||
| US08/751,189 US5919656A (en) | 1996-11-15 | 1996-11-15 | Genes encoding telomerase protein 1 |
| US87303997A | 1997-06-11 | 1997-06-11 | |
| US08/873,039 | 1997-06-11 | ||
| US08/951,733 | 1997-10-16 | ||
| US08/951,733 US7390891B1 (en) | 1996-11-15 | 1997-10-16 | Polynucleotides encoding a telomerase component TP2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1998021343A1 WO1998021343A1 (en) | 1998-05-22 |
| WO1998021343B1 true WO1998021343B1 (en) | 1998-07-30 |
| WO1998021343A8 WO1998021343A8 (en) | 2002-01-31 |
Family
ID=27419411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/021248 Ceased WO1998021343A1 (en) | 1996-11-15 | 1997-11-13 | Genes encoding telomerase proteins |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7390891B1 (en) |
| EP (1) | EP0939823A1 (en) |
| AU (1) | AU5264498A (en) |
| CA (1) | CA2271718A1 (en) |
| WO (1) | WO1998021343A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| US6777203B1 (en) | 1997-11-19 | 2004-08-17 | Geron Corporation | Telomerase promoter driving expression of therapeutic gene sequences |
| US6808880B2 (en) | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
| BR9711844A (en) | 1996-10-01 | 2000-01-18 | Geron Corp | Preparation of isolated protein, substantially pure or recombinant, isolated trt protein, substantially pure or recombinant isolated trt protein, substantially pure or recombinant, isolated trt protein or a variant thereof, or a fragment, polynucleotide, synthetic, substantially pure or recombinant, isolated nucleic acid, encoding a trt protein, expression vector, transfected cell, non-human animal, or its progeny, transgenic non-human animal, antibody or its binding fragment, antibody, specifically immunoreactive under immunologically reactive conditions, for a trt protein or its immunogenic fragment, processes of determining whether a compound or treatment is a modulator of a trt activity or expression, of determining whether a test compound is a modulator of a trt activity, of preparing recombinant telomerase, to detect a trt gene product in a sample, to detect the presence of d and at least one telomerase positive human cell in a biological sample comprising human cells, to diagnose a telomerase-related condition in a mammal, to increase the proliferative ability of a vertebrate cell in vitro, to detect the presence of a sequence of polynucleotide encoding at least a part of a trt in a biological sample, to produce a polynucleotide, to detect the expression or presence of a trt in a biological sample, uses of an ampolinucleotide, an agent that increases the expression or activity of a trt, an inhibitor of the expression or telomerase activity of a protein, variant or fragment, pharmaceutical composition, substantially purified polypeptide, isolated polynucleotide sequence, telomerase complex, composition, substantially pure telomerase, isolated trt polypeptide, isolated nucleic acid. |
| US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
| US7622549B2 (en) * | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
| JP2002508662A (en) * | 1997-06-20 | 2002-03-19 | バイエル・アクチエンゲゼルシヤフト | Catalytic subunit of human telomerase and its diagnostic and therapeutic use |
| AU748442B2 (en) | 1997-07-01 | 2002-06-06 | Cambia | Vertebrate telomerase genes and proteins and uses thereof |
| EP1571215A3 (en) * | 1997-07-01 | 2007-10-31 | Cambia Biosystems LLC | Vertebrate telomerase genes and proteins and uses thereof |
| US7378244B2 (en) | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
| AU1606999A (en) * | 1997-11-26 | 1999-06-15 | Albert Einstein College Of Medicine Of Yeshiva University | Mouse telomerase reverse transcriptase |
| JP2002509716A (en) | 1998-03-31 | 2002-04-02 | ユニバーシティ テクノロジー コーポレイション | Methods and compositions for raising an immune response to a telomerase antigen |
| US7402307B2 (en) | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| US6337200B1 (en) | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
| US7030211B1 (en) | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US6995145B1 (en) | 1999-06-04 | 2006-02-07 | Au Jessie L-S | Methods and compositions for modulating drug activity through telomere damage |
| US6492171B2 (en) | 2000-05-16 | 2002-12-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of TERT expression |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| AUPR769701A0 (en) * | 2001-09-14 | 2001-10-11 | Li, He | Telomerase inhibitory peptides and uses thereof |
| US7294708B2 (en) * | 2002-05-31 | 2007-11-13 | Beijing Institute Of Biotechnology | Telomerase reverse transcriptase fragments and uses thereof |
| KR20090079938A (en) * | 2006-10-12 | 2009-07-22 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. | Telomerase reverse transcriptase fusion proteins, nucleotides encoding them, and uses thereof |
| LT2536830T (en) | 2010-02-16 | 2019-11-11 | Ultimovacs Asa | POLYPEPTIDIDES |
| CN104981478B (en) * | 2012-09-19 | 2019-02-22 | 珍白斯凯尔有限公司 | Cell penetrating peptides, conjugates comprising the peptides, and compositions comprising the conjugates |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
| DE3218121A1 (en) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Pharmaceutical compositions for tumour treatment |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| ATE135370T1 (en) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5639613A (en) | 1992-05-13 | 1997-06-17 | Board Of Regents, University Of Texas System | Methods for cancer diagnosis and prognosis |
| US5648215A (en) | 1992-05-13 | 1997-07-15 | Board Of Regents, The University Of Texas System | Telomerase diagnostic methods |
| US5645986A (en) | 1992-05-13 | 1997-07-08 | Board Of Reagents, The University Of Texas System | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
| EP0700435A1 (en) | 1993-05-26 | 1996-03-13 | Ontario Cancer Institute | Transgenic mammals lacking expression of particular cd45 isoforms |
| US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
| WO1995013382A1 (en) | 1993-11-12 | 1995-05-18 | Geron Corporation | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5972605A (en) | 1994-07-07 | 1999-10-26 | Geron Corporation | Assays for regulators of mammalian telomerase expression |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| RO117328B1 (en) | 1994-07-07 | 2002-01-30 | Geron Corp | RAM COMPOSITION OF MAMMER TELEMATICS, RECOMBINANT PLASMID, EXPRESSION THEREOF, AND THE METHOD FOR DETECTING THE PRESENT OF A NEOPLAZIC STATE |
| US5635349A (en) | 1994-12-02 | 1997-06-03 | Tularik, Inc. | High-throughput screening assay for inhibitors of nucleic acid polymerases |
| EP0799315A2 (en) | 1994-12-19 | 1997-10-08 | Cold Spring Harbor Laboratory | Telomerase protein component |
| WO1997002279A1 (en) | 1995-07-06 | 1997-01-23 | Ctrc Research Foundation | Methods and compositions for modulation and inhibition of telomerase |
| WO1997035967A2 (en) | 1996-03-28 | 1997-10-02 | Cold Spring Harbor Laboratory | Transgenic organisms with altered telomerase activity |
| WO1997037691A1 (en) | 1996-04-10 | 1997-10-16 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
| US5770422A (en) | 1996-07-08 | 1998-06-23 | The Regents Of The University Of California | Human telomerase |
| US5747317A (en) | 1996-07-08 | 1998-05-05 | Tularik Inc. | Human telomerase RNA interacting protein gene |
| AU3798997A (en) | 1996-07-17 | 1998-02-09 | David E. Burstein | Telomerase assay for precancerous lesions of the uterine cervix |
| JPH1028600A (en) | 1996-07-17 | 1998-02-03 | Kyowa Hakko Kogyo Co Ltd | Method for measuring telomerase activity |
| WO1998007838A1 (en) | 1996-08-21 | 1998-02-26 | Mitsubishi Chemical Corporation | Higher animal telomerase protein and gene encoding the same |
| WO1998008938A1 (en) | 1996-08-28 | 1998-03-05 | Shonen Yoshida | Proteins having telomerase activity |
| AU7158896A (en) | 1996-09-13 | 1998-04-02 | Geron Corporation | Methods and reagents for regulating telomere length and telomerase activity |
| US6261836B1 (en) * | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6093809A (en) * | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| BR9711844A (en) * | 1996-10-01 | 2000-01-18 | Geron Corp | Preparation of isolated protein, substantially pure or recombinant, isolated trt protein, substantially pure or recombinant isolated trt protein, substantially pure or recombinant, isolated trt protein or a variant thereof, or a fragment, polynucleotide, synthetic, substantially pure or recombinant, isolated nucleic acid, encoding a trt protein, expression vector, transfected cell, non-human animal, or its progeny, transgenic non-human animal, antibody or its binding fragment, antibody, specifically immunoreactive under immunologically reactive conditions, for a trt protein or its immunogenic fragment, processes of determining whether a compound or treatment is a modulator of a trt activity or expression, of determining whether a test compound is a modulator of a trt activity, of preparing recombinant telomerase, to detect a trt gene product in a sample, to detect the presence of d and at least one telomerase positive human cell in a biological sample comprising human cells, to diagnose a telomerase-related condition in a mammal, to increase the proliferative ability of a vertebrate cell in vitro, to detect the presence of a sequence of polynucleotide encoding at least a part of a trt in a biological sample, to produce a polynucleotide, to detect the expression or presence of a trt in a biological sample, uses of an ampolinucleotide, an agent that increases the expression or activity of a trt, an inhibitor of the expression or telomerase activity of a protein, variant or fragment, pharmaceutical composition, substantially purified polypeptide, isolated polynucleotide sequence, telomerase complex, composition, substantially pure telomerase, isolated trt polypeptide, isolated nucleic acid. |
| US6475789B1 (en) * | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US6337200B1 (en) * | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
-
1997
- 1997-10-16 US US08/951,733 patent/US7390891B1/en not_active Expired - Fee Related
- 1997-11-13 EP EP97947600A patent/EP0939823A1/en not_active Withdrawn
- 1997-11-13 CA CA002271718A patent/CA2271718A1/en not_active Abandoned
- 1997-11-13 WO PCT/US1997/021248 patent/WO1998021343A1/en not_active Ceased
- 1997-11-13 AU AU52644/98A patent/AU5264498A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998021343B1 (en) | Genes encoding telomerase proteins | |
| CA2087261A1 (en) | Purification directed cloning of peptides | |
| JP4189035B2 (en) | Recombinant human interferon-beta with improved solubility | |
| WO1998056927A3 (en) | Nucleic acids encoding polypeptide having protease activity | |
| Kimura et al. | Complete Amino Acid Sequence of Crystalline (α–Glucosidase from Aspergillus niger | |
| EP0889133A3 (en) | Process for producing microbial transglutaminase | |
| CA2249233A1 (en) | Mch4 and mch5, apoptotic protease, nucleic acids encoding and methods of use | |
| WO2000006726A3 (en) | Delta-related polypeptides | |
| AU653526B2 (en) | Novel signal sequences | |
| EP0857789A3 (en) | Ferulic acid decarboxylase | |
| WO2000000607B1 (en) | A nucleic acid encoding a retinoblastoma binding protein (rbp-7) and polymorphic markers associated with said nucleic acid | |
| EP0139501A3 (en) | The manufacture and expression of genes for thaumatin | |
| AU8649698A (en) | Cell cycle-regulating proteins | |
| CA2253006A1 (en) | .beta.-carotene hydroxylase gene | |
| US7771970B2 (en) | Process for preparation of polypeptides of interest from fusion polypeptides | |
| CA2384122A1 (en) | Cyclic depsipeptide synthetase and gene thereof, and mass production system for cyclic depsipeptide | |
| CA2241786A1 (en) | Novel amp activated protein kinase | |
| WO1999054436A3 (en) | Nucleic acids and proteins of c. elegans insulin-like genes and uses thereof | |
| WO2002010384A1 (en) | Genes encoding proteins capable of regenerating luciferin, recombinant dna and process for producing protein capable of regenerating luciferin | |
| KR920000932A (en) | Enzymes and DNA encoding them | |
| CA2348732A1 (en) | Human h37 proteins and cdnas encoding the same | |
| EP0845536A3 (en) | Protein having ethylenediamine-N,N'-disuccinic acid: ethylenediamine lyase activity and gene encoding the same | |
| KR20030034136A (en) | Fusion protein containing additional cationic amino acids and improvement of bio-operation by using same | |
| WO2002010383A1 (en) | Genes encoding proteins capable of regenerating luciferin, recombinant dna and process for producing protein capable of regenerating luciferin | |
| WO2003025182A1 (en) | Dna for overexpression of growth hormone and utilization thereof |